EP4734993A2 - Verfahren zur sensibilisierung wirkstoffresistenter krebszellen - Google Patents

Verfahren zur sensibilisierung wirkstoffresistenter krebszellen

Info

Publication number
EP4734993A2
EP4734993A2 EP24833157.1A EP24833157A EP4734993A2 EP 4734993 A2 EP4734993 A2 EP 4734993A2 EP 24833157 A EP24833157 A EP 24833157A EP 4734993 A2 EP4734993 A2 EP 4734993A2
Authority
EP
European Patent Office
Prior art keywords
cancer
subject
biomarker
cells
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24833157.1A
Other languages
English (en)
French (fr)
Inventor
Cigall Kadoch
Claudia Gentile
Katerina Politi
Fernando DE MIGUEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Dana Farber Cancer Institute Inc
Original Assignee
Yale University
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Dana Farber Cancer Institute Inc filed Critical Yale University
Publication of EP4734993A2 publication Critical patent/EP4734993A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP24833157.1A 2023-06-30 2024-07-01 Verfahren zur sensibilisierung wirkstoffresistenter krebszellen Pending EP4734993A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363524563P 2023-06-30 2023-06-30
US202363526676P 2023-07-13 2023-07-13
PCT/US2024/036441 WO2025007147A2 (en) 2023-06-30 2024-07-01 Methods for sensitizing drug-resistant cancer cells

Publications (1)

Publication Number Publication Date
EP4734993A2 true EP4734993A2 (de) 2026-05-06

Family

ID=93939996

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24833157.1A Pending EP4734993A2 (de) 2023-06-30 2024-07-01 Verfahren zur sensibilisierung wirkstoffresistenter krebszellen

Country Status (2)

Country Link
EP (1) EP4734993A2 (de)
WO (1) WO2025007147A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609402D0 (en) * 2016-05-27 2016-07-13 Cancer Res Inst Royal Materials and methods for treating cancer
EP3529315B1 (de) * 2016-10-21 2024-12-04 Da Zen Theranostics, Inc An ein statin konjugiertes nahinfrarot (nir)-farbstoffkrebsmittel
PT3837256T (pt) * 2018-08-17 2023-05-23 Novartis Ag Compostos e composições de ureia como inibidores de smarca2/brm-atpase

Also Published As

Publication number Publication date
WO2025007147A2 (en) 2025-01-02
WO2025007147A3 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
Li et al. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression
de Miguel et al. Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Gooding et al. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers
Liang et al. Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation
Ganci et al. PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma
Liao et al. A feedback circuitry between polycomb signaling and fructose-1, 6-bisphosphatase enables hepatic and renal tumorigenesis
EP3467124A1 (de) Verfahren zur diagnose, prognose und behandlung von lungenkrebsmetastasen
Chang et al. MiRNA‐516a promotes bladder cancer metastasis by inhibiting MMP9 protein degradation via the AKT/FOXO3A/SMURF1 axis
Topka et al. Targeting germline-and tumor-associated nucleotide excision repair defects in cancer
US12290521B2 (en) Methods and materials for identifying and treating BET inhibitor-resistant cancers
US20160113911A1 (en) Methods and compositions for the treatment of cancer
Luo et al. CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression
Zhang et al. Targeting histone modifiers in bladder cancer therapy—preclinical and clinical evidence
Gbenedio et al. RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer
Andreani et al. SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Xu et al. GNA14’s interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway
JP2012512157A (ja) 癌を治療するためのエンザスタウリン
Galan-Cobo et al. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer
Gritti et al. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming
Lulla et al. Neutrophil elastase remodels mammary tumors to facilitate lung metastasis
EP3092492B1 (de) Behandlung von mutiertem p53 exprimierenden tumoren
Grawenda et al. Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer
WO2025007147A2 (en) Methods for sensitizing drug-resistant cancer cells
Ma et al. MBIP promotes ESCC metastasis by activating MAPK pathway
Li et al. Histone demethylase LSD1 promotes castration‐resistant prostate cancer by causing widespread gene expression derangements

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE